Harvard Bioscience Analyst Price Targets

Wall Street analyst price targets and consensus rating for Harvard Bioscience (HBIO).

Price Target Range — 5 Quarters

Analyst Consensus

Consensus RatingSpeculative BuyAvg. Consensus PT$19Upside to Avg. PT+131.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 12, 2026	Benchmark	Bruce D. Jackson	PT Raise	Speculative Buy	$6→$8
Mar 16, 2026	Benchmark	Bruce D. Jackson	PT Raise	Speculative Buy	$1→$6
Mar 13, 2026	Benchmark	Bruce D. Jackson	PT Cut	Speculative Buy	$2→$1
Sep 10, 2025	Benchmark	Bruce D. Jackson	PT Cut	Speculative Buy	$3→$2
May 13, 2025	Benchmark	Bruce Jackson	PT Cut	Speculative Buy	$5→$3
Apr 9, 2025	Keybanc	Paul Knight	Downgrade	Overweight→Sector Weight	—
Mar 24, 2025	Benchmark	Bruce Jackson	PT Cut	Speculative Buy	$6→$5

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $6 to $7.5.

Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $0.6 to $6.

Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $0.6

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $2 to $0.6.

Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $2

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $3 to $2.

Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $3

Benchmark analyst Bruce Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $4.5 to $3.

Benzinga Newsdesk

PRO
Keybanc Downgrades Harvard Bioscience to Sector Weight

Keybanc analyst Paul Knight downgrades Harvard Bioscience (NASDAQ:HBIO) from Overweight to Sector Weight.

Benzinga Newsdesk

Harvard Bioscience Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Harvard Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $0.6

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $2

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $3

PRO
Keybanc Downgrades Harvard Bioscience to Sector Weight

People Also Watch

People Also Watch

Harvard Bioscience Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Harvard Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBenchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5

PROBenchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6

PROBenchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $0.6

PROBenchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $2

PROBenchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $3

PROKeybanc Downgrades Harvard Bioscience to Sector Weight

People Also Watch

People Also Watch

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $0.6

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $2

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $3

PRO
Keybanc Downgrades Harvard Bioscience to Sector Weight